8 August 2007

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
(NICE)
Peter House
Oxford Road
Manchester
M1 5AN



Quarry House Quarry Hill Leeds LS2 7UE


Tel:

Dear Carole

Single Technology Appraisal — Velcade (bortezomib) for multiple myeloma

Further to the Velcade responder scheme in terms of responder definition are acceptable to the Department of Health.

Yours sincerely



Medicines, Pharmacy and Industry Group